Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. (Q53118752)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published in April 2013

Language	Label	Description	Also known as
English	Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.	scientific article published in April 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

myasthenia gravis

0 references

neuromuscular junction

1 reference

based on heuristic

inferred from title

Lambert-Eaton myasthenic syndrome

1 reference

based on heuristic

inferred from title

Maarten J. Titulaer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Jan J Verschuuren

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Agnes van Sonderen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Paul W Wirtz

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Current treatment options in neurology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

224-239

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Immunology of paraneoplastic syndromes: overview

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Myasthenia gravis: a changing pattern of incidence

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

A systematic review of population based epidemiological studies in Myasthenia Gravis.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Myasthenia gravis requiring pyridostigmine treatment in a national population cohort

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

The Role of Thymomas in the Development of Myasthenia Gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Neuromyotonia: clinical profile of twenty cases from northwest India

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Morvan syndrome: clinical and serological observations in 29 cases

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Paraneoplastic Isaacs' syndrome: a case series and review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Phenotypic variants of autoimmune peripheral nerve hyperexcitability

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Autoimmune Disorders of Neuronal Potassium Channels

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Treatment of myasthenia gravis: focus on pyridostigmine.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Clinical aspects of MuSK antibody positive seronegative MG.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Available treatment options for the management of Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Treatment for Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Corticosteroids for myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

The effect of prednisone on the progression from ocular to generalized myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Intravenous immunoglobulin for myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Comparison of IVIg and PLEX in patients with myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Successful immunoglobulin treatment in a patient with neuromyotonia

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Management of Voltage-Gated Potassium Channel Antibody Disorders

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

A Review: The Use of Rituximab in Neuromuscular Diseases

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Successful treatment of refractory generalized myasthenia gravis with rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Long-lasting treatment effect of rituximab in MuSK myasthenia.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Response of patients with refractory myasthenia gravis to rituximab: a retrospective study

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Use and monitoring of low dose rituximab in myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Mycophenolate mofetil for ocular myasthenia

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Tacrolimus for myasthenia gravis: a clinical study of 212 patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

High dose cyclophosphamide for severe refractory myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0213-6

21 January 2018

Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valproic acid in Isaacs-Mertens syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical therapeutic trial of cyclosporine in myasthenia gravis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of plasma exchange in myasthenia. Results of a randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Screening for Small-Cell Lung Cancer: A Follow-Up Study of Patients With Lambert-Eaton Myasthenic Syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23263888

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11940-012-0213-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23263888%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53118752&oldid=2211999705"